Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.
The report details the trend, potential and market size of Blood Cancer Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Blood Cancer Drugsmarket, defines the market attractiveness level of Blood Cancer Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Blood Cancer Drugs industry, describes the types of Blood Cancer Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Blood Cancer Drugs market and the development prospects and opportunities of Blood Cancer Drugs industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Blood Cancer Drugs market in Chapter 13.
By Player:
Bristol-Myers Squibb Company,
Pfizer Inc,
AstraZeneca PLC,
Novartis,
Astellas Pharma Inc,
Amgen Inc,
Takeda Pharmaceutical Company Ltd,
Bayer AG,
Johnson & Johnson,
Eli Lilly,
Celgene Corporation,
By Type:
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
By End-User:
Leukemia
lymphoma
Multiple Myeloma
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Blood Cancer Drugs Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Blood Cancer Drugs Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Blood Cancer Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Blood Cancer Drugs Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Blood Cancer Drugs Market Analysis and Outlook to 2022
-
7.1 Global Blood Cancer Drugs Consumption (2017-2022)
-
7.2 United States Blood Cancer Drugs Consumption (2017-2022)
-
7.3 Europe Blood Cancer Drugs Consumption (2017-2022)
-
7.4 China Blood Cancer Drugs Consumption (2017-2022)
-
7.5 Japan Blood Cancer Drugs Consumption (2017-2022)
-
7.6 India Blood Cancer Drugs Consumption (2017-2022)
-
7.7 South Korea Blood Cancer Drugs Consumption (2017-2022)
8 Region and Country-wise Blood Cancer Drugs Market Analysis and Outlook to 2028
-
8.1 Global Blood Cancer Drugs Consumption Forecast (2022-2028)
-
8.2 United States Blood Cancer Drugs Consumption Forecast (2022-2028)
-
8.3 Europe Blood Cancer Drugs Consumption Forecast (2022-2028)
-
8.4 China Blood Cancer Drugs Consumption Forecast (2022-2028)
-
8.5 Japan Blood Cancer Drugs Consumption Forecast (2022-2028)
-
8.6 India Blood Cancer Drugs Consumption Forecast (2022-2028)
-
8.7 South Korea Blood Cancer Drugs Consumption Forecast (2022-2028)
9 Global Blood Cancer Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Blood Cancer Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Blood Chemotherapy Drugs Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Blood Targeted Therapy Drugs Consumption and Growth Rate (2017-2022)
-
9.2 Global Blood Cancer Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Leukemia Consumption and Growth Rate (2017-2022)
-
9.2.2 Global lymphoma Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Multiple Myeloma Consumption and Growth Rate (2017-2022)
10 Global Blood Cancer Drugs Market Outlook by Types and Applications to 2028
-
10.1 Global Blood Cancer Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Blood Chemotherapy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Blood Targeted Therapy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Blood Cancer Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Leukemia Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global lymphoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
11 Global Blood Cancer Drugs Import and Export Analysis (Top 5 Countries)
-
11.1 Global Blood Cancer Drugs Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Blood Cancer Drugs Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Blood Cancer Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Blood Cancer Drugs Market Competitive Analysis
-
14.1 Bristol-Myers Squibb Company,
-
14.1.1 Bristol-Myers Squibb Company, Company Details
-
14.1.2 Bristol-Myers Squibb Company, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Product and Service
-
14.2 Pfizer Inc,
-
14.2.1 Pfizer Inc, Company Details
-
14.2.2 Pfizer Inc, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Pfizer Inc, Blood Cancer Drugs Product and Service
-
14.3 AstraZeneca PLC,
-
14.3.1 AstraZeneca PLC, Company Details
-
14.3.2 AstraZeneca PLC, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 AstraZeneca PLC, Blood Cancer Drugs Product and Service
-
14.4 Novartis,
-
14.4.1 Novartis, Company Details
-
14.4.2 Novartis, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Novartis, Blood Cancer Drugs Product and Service
-
14.5 Astellas Pharma Inc,
-
14.5.1 Astellas Pharma Inc, Company Details
-
14.5.2 Astellas Pharma Inc, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Astellas Pharma Inc, Blood Cancer Drugs Product and Service
-
14.6 Amgen Inc,
-
14.6.1 Amgen Inc, Company Details
-
14.6.2 Amgen Inc, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Amgen Inc, Blood Cancer Drugs Product and Service
-
14.7 Takeda Pharmaceutical Company Ltd,
-
14.7.1 Takeda Pharmaceutical Company Ltd, Company Details
-
14.7.2 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product and Service
-
14.8 Bayer AG,
-
14.8.1 Bayer AG, Company Details
-
14.8.2 Bayer AG, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Bayer AG, Blood Cancer Drugs Product and Service
-
14.9 Johnson & Johnson,
-
14.9.1 Johnson & Johnson, Company Details
-
14.9.2 Johnson & Johnson, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Johnson & Johnson, Blood Cancer Drugs Product and Service
-
14.10 Eli Lilly,
-
14.10.1 Eli Lilly, Company Details
-
14.10.2 Eli Lilly, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Eli Lilly, Blood Cancer Drugs Product and Service
-
14.11 Celgene Corporation,
-
14.11.1 Celgene Corporation, Company Details
-
14.11.2 Celgene Corporation, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Celgene Corporation, Blood Cancer Drugs Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Blood Cancer Drugs
-
Figure Blood Cancer Drugs Picture
-
Table Global Blood Cancer Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Blood Cancer Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Blood Cancer Drugs Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Blood Cancer Drugs Consumption by Country (2017-2022)
-
Figure United States Blood Cancer Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Blood Cancer Drugs Consumption and Growth Rate (2017-2022)
-
Figure China Blood Cancer Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Blood Cancer Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Blood Cancer Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Blood Cancer Drugs Consumption and Growth Rate (2017-2022)
-
Figure Global Blood Cancer Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Blood Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Blood Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Blood Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Blood Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Blood Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Blood Cancer Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Blood Chemotherapy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Global Blood Targeted Therapy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Global Leukemia Consumption and Growth Rate (2017-2022)
-
Figure Global lymphoma Consumption and Growth Rate (2017-2022)
-
Figure Global Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure Global Blood Chemotherapy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Blood Targeted Therapy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Leukemia Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global lymphoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Blood Cancer Drugs Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Blood Cancer Drugs Export by Region (Top 5 Countries) (2017-2028)
-
Table Bristol-Myers Squibb Company, (Foundation Year, Company Profile and etc.)
-
Table Bristol-Myers Squibb Company, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Company, Blood Cancer Drugs Product and Service
-
Table Pfizer Inc, (Foundation Year, Company Profile and etc.)
-
Table Pfizer Inc, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Inc, Blood Cancer Drugs Product and Service
-
Table AstraZeneca PLC, (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca PLC, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca PLC, Blood Cancer Drugs Product and Service
-
Table Novartis, (Foundation Year, Company Profile and etc.)
-
Table Novartis, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis, Blood Cancer Drugs Product and Service
-
Table Astellas Pharma Inc, (Foundation Year, Company Profile and etc.)
-
Table Astellas Pharma Inc, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas Pharma Inc, Blood Cancer Drugs Product and Service
-
Table Amgen Inc, (Foundation Year, Company Profile and etc.)
-
Table Amgen Inc, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Inc, Blood Cancer Drugs Product and Service
-
Table Takeda Pharmaceutical Company Ltd, (Foundation Year, Company Profile and etc.)
-
Table Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product and Service
-
Table Bayer AG, (Foundation Year, Company Profile and etc.)
-
Table Bayer AG, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer AG, Blood Cancer Drugs Product and Service
-
Table Johnson & Johnson, (Foundation Year, Company Profile and etc.)
-
Table Johnson & Johnson, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Johnson & Johnson, Blood Cancer Drugs Product and Service
-
Table Eli Lilly, (Foundation Year, Company Profile and etc.)
-
Table Eli Lilly, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly, Blood Cancer Drugs Product and Service
-
Table Celgene Corporation, (Foundation Year, Company Profile and etc.)
-
Table Celgene Corporation, Blood Cancer Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celgene Corporation, Blood Cancer Drugs Product and Service
-
